Schizophrenia Clinical Trial
Official title:
The Effect of Recognition and Expression of Emotions Program Applied to Schizophrenia Patients Applying to Community Mental Health Center on Alexithymia and Emotion Expression
Verified date | October 2023 |
Source | Sinop University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
As a result of the positive and negative symptoms that occur in schizophrenia, patients with schizophrenia may experience negative emotions more frequently than individuals with other mental problems. Since these emotions can trigger psychotic symptoms, there is a need to develop effective emotion regulation strategies to be applied to patients with schizophrenia. Aim: In this study, it was aimed to examine the effect of emotion recognition and expression program on alexithymia and emotion expression in patients with schizophrenia.
Status | Completed |
Enrollment | 36 |
Est. completion date | May 15, 2023 |
Est. primary completion date | May 15, 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 90 Years |
Eligibility | Inclusion Criteria: - Patient who had received a diagnosis of schizophrenia and comes to the Community Mental Health Center regularly, - Being able to read and communicate - Being 18 years of age or older, - Not having mental retardation, - Not having insight, understanding, hearing problems, - Being in remission, - Volunteering to study Exclusion Criteria: - Not diagnosed with clinical schizophrenia, - Being under the age of 18, - Having mental retardation, - Having no insight, - Not understanding and hearing, - Not in remission - Refusing to participate in the study - Stop studying at any stage of the study |
Country | Name | City | State |
---|---|---|---|
Turkey | Sinop Community Mental Health Center | Sinop |
Lead Sponsor | Collaborator |
---|---|
Sinop University |
Turkey,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Emotion Recognition and Expression | Expression of Emotions Scale is used to measure the state of expression of emotions. The scale was developed by King and Emmons (1990), and its Turkish validity and reliability were verified by Kuzucu (2011). The measurement tool consists of a total of 16 items and 3 sub-dimensions. It has positive, negative and closeness sub-dimensions. It is a 7-point Likert type scale .The scores to be taken from the scale vary between 15 and 105, and as the scores obtained increase, it is seen that the tendency of the individual to express emotion increases. The scale provides information about expressing emotions both in interpersonal relationships and independent of interpersonal relationships. A high score indicates a high tendency to express emotions. | One day | |
Primary | Alexithymia | Toronto Alexithymia Scale (TAS): The scale was developed by Bagby et al. (1994) Güleç et al. (2009) adapted into Turkish. The scale consists of 20 items, has three sub-dimensions and is in a 5-point Likert type. High scores indicate high alexithymic level. There are sub-dimensions of difficulty in recognizing emotions, difficulty in putting emotions into words, and extroverted thinking. | One day | |
Primary | Positive and Negative Syndrome | Positive and Negative Syndrome Scale (PANNS): The scale evaluating positive and negative symptoms in schizophrenia was developed by Kay et al (1987) and Kostakoglu et al. It was adapted into Turkish by (1999). Consisting of 30 items, the scale has three sub-dimensions. A 7-point severity assessment is carried out. Seven of the items of the scale belong to the positive symptoms subscale, seven to the negative symptoms subscale, and the remaining sixteen to the general psychopathology subscale. | One day |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05039489 -
A Study on the Brain Mechanism of cTBS in Improving Medication-resistant Auditory Hallucinations in Schizophrenia
|
N/A | |
Completed |
NCT05111548 -
Brain Stimulation and Cognitive Training - Efficacy
|
N/A | |
Completed |
NCT05321602 -
Study to Evaluate the PK Profiles of LY03010 in Patients With Schizophrenia or Schizoaffective Disorder
|
Phase 1 | |
Completed |
NCT04503954 -
Efficacy of Chronic Disease Self-management Program in People With Schizophrenia
|
N/A | |
Completed |
NCT02831231 -
Pilot Study Comparing Effects of Xanomeline Alone to Xanomeline Plus Trospium
|
Phase 1 | |
Completed |
NCT05517460 -
The Efficacy of Auricular Acupressure on Improving Constipation Among Residents in Community Rehabilitation Center
|
N/A | |
Completed |
NCT03652974 -
Disturbance of Plasma Cytokine Parameters in Clozapine-Resistant Treatment-Refractory Schizophrenia (CTRS) and Their Association With Combination Therapy
|
Phase 4 | |
Recruiting |
NCT04012684 -
rTMS on Mismatch Negativity of Schizophrenia
|
N/A | |
Recruiting |
NCT04481217 -
Cognitive Factors Mediating the Relationship Between Childhood Trauma and Auditory Hallucinations in Schizophrenia
|
N/A | |
Completed |
NCT00212784 -
Efficacy and Safety of Asenapine Using an Active Control in Subjects With Schizophrenia or Schizoaffective Disorder (25517)(P05935)
|
Phase 3 | |
Completed |
NCT04092686 -
A Clinical Trial That Will Study the Efficacy and Safety of an Investigational Drug in Acutely Psychotic People With Schizophrenia
|
Phase 3 | |
Completed |
NCT01914393 -
Pediatric Open-Label Extension Study
|
Phase 3 | |
Recruiting |
NCT03790345 -
Vitamin B6 and B12 in the Treatment of Movement Disorders Induced by Antipsychotics
|
Phase 2/Phase 3 | |
Recruiting |
NCT05956327 -
Insight Into Hippocampal Neuroplasticity in Schizophrenia by Investigating Molecular Pathways During Physical Training
|
N/A | |
Terminated |
NCT03209778 -
Involuntary Memories Investigation in Schizophrenia
|
N/A | |
Terminated |
NCT03261817 -
A Controlled Study With Remote Web-based Adapted Physical Activity (e-APA) in Psychotic Disorders
|
N/A | |
Completed |
NCT02905604 -
Magnetic Stimulation of the Brain in Schizophrenia or Depression
|
N/A | |
Recruiting |
NCT05542212 -
Intra-cortical Inhibition and Cognitive Deficits in Schizophrenia
|
N/A | |
Completed |
NCT04411979 -
Effects of 12 Weeks Walking on Cognitive Function in Schizophrenia
|
N/A | |
Terminated |
NCT03220438 -
TMS Enhancement of Visual Plasticity in Schizophrenia
|
N/A |